BTX - Brooklyn ImmunoTherapeutics acquires license for mRNA technology platform

Brooklyn ImmunoTherapeutics (BTX) has climbed ~14.3% in the post-market trading after announcing the acquisition of a license for an mRNA technology platform for $1M.With the purchase of the license for Factor Bioscience’s and Novellus’ MRNA gene editing and cell therapies technology, the company has also extended its option exercise period through May 31, 2021.The option allows Brooklyn ImmunoTherapeutics to enter into a related license agreement with Factor Bioscience and Novellus for the development of gene-edited compounds using mRNA based on a patented process, the company said.If the option is not exercised by May 31, Brooklyn ImmunoTherapeutics is entitled to be reimbursed for the $1 million payment.Recently, the company appointed Howard J. Federoff as its new CEO.

For further details see:

Brooklyn ImmunoTherapeutics acquires license for mRNA technology platform